389 related articles for article (PubMed ID: 23752607)
21. Concurrent Inhibition of Pim and FLT3 Kinases Enhances Apoptosis of FLT3-ITD Acute Myeloid Leukemia Cells through Increased Mcl-1 Proteasomal Degradation.
Kapoor S; Natarajan K; Baldwin PR; Doshi KA; Lapidus RG; Mathias TJ; Scarpa M; Trotta R; Davila E; Kraus M; Huszar D; Tron AE; Perrotti D; Baer MR
Clin Cancer Res; 2018 Jan; 24(1):234-247. PubMed ID: 29074603
[No Abstract] [Full Text] [Related]
22. Mutation analysis of SHIP gene in acute leukemia.
Luo JM; Liu ZL; Hao HL; Wang FX; Dong ZR; Ohno R
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2004 Aug; 12(4):420-6. PubMed ID: 15363123
[TBL] [Abstract][Full Text] [Related]
23. Increased IkappaB kinase activity is associated with activated NF-kappaB in acute myeloid blasts.
Baumgartner B; Weber M; Quirling M; Fischer C; Page S; Adam M; Von Schilling C; Waterhouse C; Schmid C; Neumeier D; Brand K
Leukemia; 2002 Oct; 16(10):2062-71. PubMed ID: 12357358
[TBL] [Abstract][Full Text] [Related]
24. Molecular pathway activation features of pediatric acute myeloid leukemia (AML) and acute lymphoblast leukemia (ALL) cells.
Petrov I; Suntsova M; Mutorova O; Sorokin M; Garazha A; Ilnitskaya E; Spirin P; Larin S; Kovalchuk O; Prassolov V; Zhavoronkov A; Roumiantsev A; Buzdin A
Aging (Albany NY); 2016 Nov; 8(11):2936-2947. PubMed ID: 27870639
[TBL] [Abstract][Full Text] [Related]
25. Aberrant nuclear factor-kappa B activity in acute myeloid leukemia: from molecular pathogenesis to therapeutic target.
Zhou J; Ching YQ; Chng WJ
Oncotarget; 2015 Mar; 6(8):5490-500. PubMed ID: 25823927
[TBL] [Abstract][Full Text] [Related]
26. The PIM family of oncoproteins: small kinases with huge implications in myeloid leukemogenesis and as therapeutic targets.
Saurabh K; Scherzer MT; Shah PP; Mims AS; Lockwood WW; Kraft AS; Beverly LJ
Oncotarget; 2014 Sep; 5(18):8503-14. PubMed ID: 25238262
[TBL] [Abstract][Full Text] [Related]
27. [NF-κB activity in myeloid leukemia stem cells].
Kagoya Y
Rinsho Ketsueki; 2015 Apr; 56(4):384-91. PubMed ID: 25971268
[TBL] [Abstract][Full Text] [Related]
28. Absolute levels of MDR-1, MRP, and BCL-2 MRNA and tumor remission in acute leukemia.
Köhler T; Leiblein S; Borchert S; Eller J; Rost AK; Lassner D; Krahl R; Helbig W; Wagner O; Remke H
Adv Exp Med Biol; 1999; 457():177-85. PubMed ID: 10500792
[TBL] [Abstract][Full Text] [Related]
29. Constitutive NF-kappab/Rel activation in philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia (ALL).
Munzert G; Kirchner D; Ottmann O; Bergmann L; Schmid RM
Leuk Lymphoma; 2004 Jun; 45(6):1181-4. PubMed ID: 15359998
[TBL] [Abstract][Full Text] [Related]
30. [Regulation of NF-kappaB/P65 by MDM2 in acute lymphoblastic leukemia in childhood].
Hu Q; Zhou MX; Liu SY; Zhang LQ; Liu AQ; Guo YJ; Song Y
Zhonghua Er Ke Za Zhi; 2003 Dec; 41(12):921-4. PubMed ID: 14723816
[TBL] [Abstract][Full Text] [Related]
31. Increase sensitivity to chemotherapeutical agents and cytoplasmatic interaction between NPM leukemic mutant and NF-kappaB in AML carrying NPM1 mutations.
Cilloni D; Messa F; Rosso V; Arruga F; Defilippi I; Carturan S; Catalano R; Pautasso M; Panuzzo C; Nicoli P; Messa E; Morotti A; Iacobucci I; Martinelli G; Bracco E; Saglio G
Leukemia; 2008 Jun; 22(6):1234-40. PubMed ID: 18401421
[TBL] [Abstract][Full Text] [Related]
32. RSK2 is a new Pim2 target with pro-survival functions in FLT3-ITD-positive acute myeloid leukemia.
Hospital MA; Jacquel A; Mazed F; Saland E; Larrue C; Mondesir J; Birsen R; Green AS; Lambert M; Sujobert P; Gautier EF; Salnot V; Le Gall M; Decroocq J; Poulain L; Jacque N; Fontenay M; Kosmider O; Récher C; Auberger P; Mayeux P; Bouscary D; Sarry JE; Tamburini J
Leukemia; 2018 Mar; 32(3):597-605. PubMed ID: 28914261
[TBL] [Abstract][Full Text] [Related]
33. Expression of constitutively active nuclear-kappa B RelA transcription factor in blasts of acute myeloid leukemia.
Bueso-Ramos CE; Rocha FC; Shishodia S; Medeiros LJ; Kantarjian HM; Vadhan-Raj S; Estrov Z; Smith TL; Nguyen MH; Aggarwal BB
Hum Pathol; 2004 Feb; 35(2):246-53. PubMed ID: 14991544
[TBL] [Abstract][Full Text] [Related]
34. Expression of CD133 in acute leukemia.
Tolba FM; Foda ME; Kamal HM; Elshabrawy DA
Med Oncol; 2013 Jun; 30(2):527. PubMed ID: 23532815
[TBL] [Abstract][Full Text] [Related]
35. SPARC promotes leukemic cell growth and predicts acute myeloid leukemia outcome.
Alachkar H; Santhanam R; Maharry K; Metzeler KH; Huang X; Kohlschmidt J; Mendler JH; Benito JM; Hickey C; Neviani P; Dorrance AM; Anghelina M; Khalife J; Tarighat SS; Volinia S; Whitman SP; Paschka P; Hoellerbauer P; Wu YZ; Han L; Bolon BN; Blum W; Mrózek K; Carroll AJ; Perrotti D; Andreeff M; Caligiuri MA; Konopleva M; Garzon R; Bloomfield CD; Marcucci G
J Clin Invest; 2014 Apr; 124(4):1512-24. PubMed ID: 24590286
[TBL] [Abstract][Full Text] [Related]
36. Characteristics of CARMA1-BCL10-MALT1-A20-NF-κB expression in T cell-acute lymphocytic leukemia.
Ma Y; Liao Z; Xu Y; Zhong Z; Wang X; Zhang F; Chen S; Yang L; Luo G; Huang X; Huang S; Wu X; Li Y
Eur J Med Res; 2014 Nov; 19(1):62. PubMed ID: 25384343
[TBL] [Abstract][Full Text] [Related]
37. The relationship between bcl-2 expression and response to chemotherapy in acute leukaemia.
Maung ZT; MacLean FR; Reid MM; Pearson AD; Proctor SJ; Hamilton PJ; Hall AG
Br J Haematol; 1994 Sep; 88(1):105-9. PubMed ID: 7803231
[TBL] [Abstract][Full Text] [Related]
38. The serine/threonine kinase Pim-2 is a novel anti-apoptotic mediator in myeloma cells.
Asano J; Nakano A; Oda A; Amou H; Hiasa M; Takeuchi K; Miki H; Nakamura S; Harada T; Fujii S; Kagawa K; Endo I; Yata K; Sakai A; Ozaki S; Matsumoto T; Abe M
Leukemia; 2011 Jul; 25(7):1182-8. PubMed ID: 21475253
[TBL] [Abstract][Full Text] [Related]
39. Acquired expression of osteopontin selectively promotes enrichment of leukemia stem cells through AKT/mTOR/PTEN/β-catenin pathways in AML cells.
Mohammadi S; Ghaffari SH; Shaiegan M; Zarif MN; Nikbakht M; Akbari Birgani S; Alimoghadam K; Ghavamzadeh A
Life Sci; 2016 May; 152():190-8. PubMed ID: 27063991
[TBL] [Abstract][Full Text] [Related]
40. [Expression of p16INK4a, p15INK4b, p21WAF1/Clip1 cell cycle inhibitors on blastic cells in patients with acute myeloblastic leukemia (AML) and acute lymphoblastic leukemia (ALL) ].
Kapelko-Słowik K; Wołowiec D; Sedek K; Jaźwiec B; Urbaniak-Kujda D; Kuliczkowski K
Pol Arch Med Wewn; 2002 Sep; 108(3):849-53. PubMed ID: 12600181
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
